LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles. Sign Up to like articles & get recommendations!

AN UNDETECTABLE PB MRD STATUS SHOULD BE THE THERAPEUTIC GOAL WITH VENETOCLAX THERAPY IN RELAPSED/ REFRACTORY CLL

Photo from wikipedia

Genentech; Stock Ownership: Hoffmann–La Roche. Boyer, M: Employment Leadership Position: Roche; Stock Ownership: Roche. Humphrey, K: Employment Leadership Position: Roche; Stock Ownership: Roche. Jiang, Y: Employment Leadership Position: Genentech; Stock… Click to show full abstract

Genentech; Stock Ownership: Hoffmann–La Roche. Boyer, M: Employment Leadership Position: Roche; Stock Ownership: Roche. Humphrey, K: Employment Leadership Position: Roche; Stock Ownership: Roche. Jiang, Y: Employment Leadership Position: Genentech; Stock Ownership: Genentech. Kater, A: Consultant Advisory Role: AbbVie; Honoraria: Abbvie; Research Funding: Genetech, Roche, AbbVie; Other Remuneration: Travel, accommodations, expenses: Roche.

Keywords: employment leadership; roche; stock ownership; leadership position

Journal Title: Hematological Oncology
Year Published: 2019

Link to full text (if available)


Share on Social Media:                               Sign Up to like & get
recommendations!

Related content

More Information              News              Social Media              Video              Recommended



                Click one of the above tabs to view related content.